Hemostasis Today

September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Jean Connors: Safety of Heparin Re-Exposure in Patients with Remote HIT
Sep 23, 2026, 04:13

Jean Connors: Safety of Heparin Re-Exposure in Patients with Remote HIT

Jean Connors, Chief of Cancer Hematology at Dana-Farber Cancer Institute, shared Journal of Thrombosis and Haemostasis‘s post on LinkedIn:

“Truly wonderful to work with the dedicated team of Brigham and Women’s Hospital pharmacists Elizabeth Caudill, Ju Hee Kim, Dareen Kanaan, Katelyn Sylvester, Liriany Pimentel Rodriguez, Christine Kim as part our Hemostatic Antithrombotic Stewardship program, to address this important question: can patients with remote HIT be re-exposed to UFH?”

Journal of Thrombosis and Haemostasis shared a post on LinkedIn about a recent article by Elizabeth B. Caudill et al, adding:

“Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia

This single-center retrospective study followed 35 patients with prior heparin-induced thrombocytopenia who were re-exposed to heparin products. Only one (2.9 percent) developed recurrent HIT, with no associated thrombosis, bleeding, or in-hospital mortality. Median interval from HIT diagnosis to re-exposure was 8.1 years, suggesting re-exposure may be safe in remote HIT.”

Title: Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia

Authors: Elizabeth B. Caudill, Ju Hee Kim, Dareen M. Kanaan, Katelyn W. Sylvester, Liriany Y. Pimentel, Christine S. Kim, Jean M. Connors

Jean Connors: Safety of Heparin Re-Exposure in Patients with Remote HIT

Stay updated on all scientific advances with Hemostasis Today.